• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经度他雄胺或非那雄胺治疗后的海绵体组织:良性前列腺增生啮齿动物模型中的组织形态计量学研究。

The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model.

机构信息

Urogenital Research Unit, Rio de Janeiro State University, Rio de Janeiro, RJ 20551-030, Brazil.

出版信息

Asian J Androl. 2018 Sep-Oct;20(5):505-510. doi: 10.4103/aja.aja_28_18.

DOI:10.4103/aja.aja_28_18
PMID:29893293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6116690/
Abstract

Erectile dysfunction is a common side effect of finasteride and dutasteride treatments. The objective of this study was to investigate the structural changes in the penis using a benign prostatic hyperplasia (BPH) rodent model treated with dutasteride or finasteride. Sixty male rats were divided into the following groups: C, untreated control rats; C + D, control rats receiving dutasteride; C + F, control rats receiving finasteride; H, untreated spontaneously hypertensive rats (SHRs); H + D, SHRs treated with dutasteride; and H + F, SHRs treated with finasteride. Treatments were performed for 40 days, and penises were collected immediately thereafter. The organs were analyzed using histomorphometric methods to determine the cross-sectional penile area, as well as the surface density (Sv) of smooth muscle fibers, connective tissue, elastic system fibers, and sinusoidal spaces of the corpus cavernosum. The results were compared using a one-way ANOVA with Bonferroni's posttest. Groups C + D and C + F had a significantly smaller penile cross-sectional area, but more elastic system fiber Sv compared to Group C. Group C + D showed less smooth muscle Sv, and Group H showed more connective tissue but a smaller sinusoidal space Sv in the corpus cavernosum compared to Group C. Groups H + D and H + F had less smooth muscle Sv than Group H. Group H + D also had more connective tissue and elastic system fiber Sv than Group H. Both dutasteride and finasteride promoted penile modifications in the control rat penis, although this affect was greater in Group H animals. In this rodent model, dutasteride was the drug that most affected the corpus cavernosum.

摘要

勃起功能障碍是非那雄胺和度他雄胺治疗的常见副作用。本研究的目的是使用良性前列腺增生(BPH)啮齿动物模型研究度他雄胺或非那雄胺治疗后阴茎的结构变化。将 60 只雄性大鼠分为以下几组:C 组,未处理的对照组大鼠;C+D 组,接受度他雄胺的对照组大鼠;C+F 组,接受非那雄胺的对照组大鼠;H 组,未处理的自发性高血压大鼠(SHR);H+D 组,接受度他雄胺的 SHR 组;H+F 组,接受非那雄胺的 SHR 组。治疗进行了 40 天,之后立即收集阴茎。使用组织形态计量学方法分析器官,以确定阴茎的横截面积,以及海绵体平滑肌纤维、结缔组织、弹性系统纤维和窦状隙的表面密度(Sv)。使用单因素方差分析和 Bonferroni 事后检验比较结果。与 C 组相比,C+D 组和 C+F 组的阴茎横截面积明显较小,但弹性系统纤维 Sv 较多。与 C 组相比,C+D 组的平滑肌 Sv 较少,H 组的海绵体中结缔组织较多,但窦状隙 Sv 较小。与 H 组相比,H+D 组和 H+F 组的平滑肌 Sv 较少。与 H 组相比,H+D 组的结缔组织和弹性系统纤维 Sv 也较多。度他雄胺和非那雄胺都促进了对照组大鼠阴茎的改变,尽管 H 组动物的影响更大。在这种啮齿动物模型中,度他雄胺是对海绵体影响最大的药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c84/6116690/8e8be48d72ed/AJA-20-505-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c84/6116690/e0a018394cc3/AJA-20-505-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c84/6116690/bb238c5ed393/AJA-20-505-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c84/6116690/007be4a14954/AJA-20-505-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c84/6116690/8e8be48d72ed/AJA-20-505-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c84/6116690/e0a018394cc3/AJA-20-505-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c84/6116690/bb238c5ed393/AJA-20-505-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c84/6116690/007be4a14954/AJA-20-505-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c84/6116690/8e8be48d72ed/AJA-20-505-g006.jpg

相似文献

1
The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model.经度他雄胺或非那雄胺治疗后的海绵体组织:良性前列腺增生啮齿动物模型中的组织形态计量学研究。
Asian J Androl. 2018 Sep-Oct;20(5):505-510. doi: 10.4103/aja.aja_28_18.
2
Effects of the dutasteride and sildenafil association in the penis of a benign prostatic hyperplasia animal model.度他雄胺与西地那非联合用药对良性前列腺增生动物模型阴茎的影响。
Aging Male. 2020 Dec;23(5):1009-1015. doi: 10.1080/13685538.2019.1653839. Epub 2019 Aug 20.
3
Effects of dutasteride and tamsulosin on penile morphology in a rodent model.度他雄胺和坦索罗辛对啮齿动物模型阴茎形态的影响。
Int Braz J Urol. 2023 May-Jun;49(3):320-333. doi: 10.1590/S1677-5538.IBJU.2022.0583.
4
The Effects of Oral 5-alpha Reductase Inhibitors on Penile Intracavernosal Pressures and Penile Morphology in Rat Model.口服5-α还原酶抑制剂对大鼠模型阴茎海绵体内压力和阴茎形态的影响
Urol J. 2019 May 5;16(2):205-211. doi: 10.22037/uj.v0i0.4164.
5
A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.一项针对良性前列腺增生症患者的 5α-还原酶抑制剂的 5 年回顾性分析:非那雄胺在改善尿症状疗效和前列腺体积缩小方面与度他雄胺相当,但性副作用和乳房并发症较少。
Int J Clin Pract. 2012 Nov;66(11):1052-5. doi: 10.1111/j.1742-1241.2012.03010.x.
6
Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.接受度他雄胺或非那雄胺治疗的男性良性前列腺增生患者的前列腺手术率及急性尿潴留发生率。
BMC Urol. 2016 Aug 31;16(1):53. doi: 10.1186/s12894-016-0170-6.
7
Effects of oral finasteride on erectile function in a rat model.口服非那雄胺对大鼠模型勃起功能的影响。
J Sex Med. 2012 May;9(5):1328-36. doi: 10.1111/j.1743-6109.2012.02661.x. Epub 2012 Feb 29.
8
Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.比较美国良性前列腺增生男性中早期联合使用 α 受体阻滞剂和度他雄胺或非那雄胺治疗的临床和经济结局。
J Manag Care Spec Pharm. 2016 Oct;22(10):1204-14. doi: 10.18553/jmcp.2016.22.10.1204.
9
Penile histomorphometrical evaluation in hypertensive rats treated with sildenafil or enalapril alone or in combination: a comparison with normotensive and untreated hypertensive rats.西地那非或依那普利单独或联合治疗的高血压大鼠阴茎组织形态计量学评估:与正常血压大鼠及未治疗的高血压大鼠的比较
J Sex Med. 2015 Jan;12(1):39-47. doi: 10.1111/jsm.12750. Epub 2014 Nov 18.
10
Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.5α-还原酶抑制剂治疗良性前列腺增生患者的性功能障碍:一项全面综述和荟萃分析。
Andrology. 2017 Jul;5(4):671-678. doi: 10.1111/andr.12353. Epub 2017 Apr 28.

引用本文的文献

1
The post-finasteride syndrome: possible etiological mechanisms and symptoms.非那雄胺后综合征:可能的病因机制及症状
Int J Impot Res. 2023 Sep 11. doi: 10.1038/s41443-023-00759-5.
2
A clinical guide to rare male sexual disorders.男性罕见性障碍临床指南。
Nat Rev Urol. 2024 Jan;21(1):35-49. doi: 10.1038/s41585-023-00803-5. Epub 2023 Sep 5.
3
Effects of dutasteride and tamsulosin on penile morphology in a rodent model.度他雄胺和坦索罗辛对啮齿动物模型阴茎形态的影响。

本文引用的文献

1
Case of Unilateral Temporal Triangular Alopecia.单侧颞部三角形脱发病例
Indian Dermatol Online J. 2017 Mar-Apr;8(2):161. doi: 10.4103/2229-5178.202276.
2
Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.5-α还原酶抑制剂(非那雄胺、度他雄胺)的不良反应与安全性:一项系统评价
J Clin Aesthet Dermatol. 2016 Jul;9(7):56-62. Epub 2016 Jul 1.
3
Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.
Int Braz J Urol. 2023 May-Jun;49(3):320-333. doi: 10.1590/S1677-5538.IBJU.2022.0583.
4
Histomorphometric comparison of the corpus cavernosum of rats submitted to euthanasia with ketamine and xylazine or isoflurane.采用氯胺酮和甲苯噻嗪或异氟烷处死的大鼠海绵体组织形态计量学比较。
Acta Cir Bras. 2021 Dec 8;36(11):e361103. doi: 10.1590/ACB361103. eCollection 2021.
5
Does treatment with dutasteride or finasteride has impact on renal morphology? Experimental study.度他雄胺或非那雄胺治疗对肾脏形态有影响吗?实验研究。
Acta Cir Bras. 2021 Sep 15;36(7):e360703. doi: 10.1590/ACB360703. eCollection 2021.
6
Post-finasteride syndrome: An emerging clinical problem.非那雄胺后综合征:一个新出现的临床问题。
Neurobiol Stress. 2019 Dec 26;12:100209. doi: 10.1016/j.ynstr.2019.100209. eCollection 2020 May.
7
Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia.性类固醇受体和性激素参与良性前列腺增生的当前证据。
Res Rep Urol. 2019 Jan 7;11:1-8. doi: 10.2147/RRU.S155609. eCollection 2019.
使用5-α还原酶抑制剂治疗良性前列腺增生或脱发相关的勃起功能障碍风险:基于临床实践研究数据链的人群研究
BMJ. 2016 Sep 22;354:i4823. doi: 10.1136/bmj.i4823.
4
The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates.与下尿路症状相关的良性前列腺增生症的流行病学:患病率和发病率
Urol Clin North Am. 2016 Aug;43(3):289-97. doi: 10.1016/j.ucl.2016.04.001.
5
Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.5α-还原酶抑制剂对性功能的影响:随机对照试验的荟萃分析与系统评价
J Sex Med. 2016 Sep;13(9):1297-1310. doi: 10.1016/j.jsxm.2016.07.006. Epub 2016 Jul 27.
6
Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis.5-α还原酶抑制剂(5-ARI)联合α受体阻滞剂(AB)治疗对下尿路症状/良性前列腺增生症(LUTS/BPH)患者勃起功能障碍和性欲减退的影响:一项荟萃分析的系统评价
Aging Male. 2016 Sep;19(3):175-181. doi: 10.1080/13685538.2016.1195361. Epub 2016 Jun 16.
7
Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.度他雄胺治疗男性雄激素性脱发的长期安全性和有效性。
J Dermatol. 2016 Sep;43(9):1051-8. doi: 10.1111/1346-8138.13310. Epub 2016 Feb 19.
8
The role of the sexual partner in managing erectile dysfunction.性伴侣在治疗勃起功能障碍中的作用。
Nat Rev Urol. 2016 Mar;13(3):168-77. doi: 10.1038/nrurol.2015.315. Epub 2016 Feb 2.
9
Testosterone modulates endothelial progenitor cells in rat corpus cavernosum.睾酮调节大鼠阴茎海绵体内的内皮祖细胞。
BJU Int. 2016 Jun;117(6):976-81. doi: 10.1111/bju.13438. Epub 2016 Feb 25.
10
Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?非那雄胺或度他雄胺用于药物治疗良性前列腺增生引起的男性下尿路症状?
Actas Urol Esp. 2016 May;40(4):268-9. doi: 10.1016/j.acuro.2015.12.006. Epub 2016 Jan 7.